Cardiovascular risk and COX-2 inhibition in rheumatological practice

Journal of Human Hypertension
E Justice, D M Carruthers

Abstract

The use of specific COX-2 inhibitors in place of standard nonsteroidals for the treatment of arthritis appears to reduce the risk of serious gastrointestinal toxicity in this group of patients. However, the role played by these inhibitors in the generation or exacerbation of ischaemic cardiovascular disease is less clear. Clinical studies demonstrate that hypertension can be induced or aggravated by COX-2 inhibitors to a degree similar to that which occurs with standard nonsteroidals. Endothelial dysfunction, an indicator of cardiac ischaemia, may also be exacerbated by specific COX-2 inhibition and there is much debate as to whether these changes lead to an absolute increase in ischaemic cardiac events. These effects on cardiovascular risk factors appear all the more important in patients with rheumatoid arthritis where there is an increase in the incidence of ischaemic heart disease. Here we review the available data on COX-2 inhibition and cardiovascular disease and conclude that all patients who started these agents should have a careful assessment and modification of any cardiovascular risk factors.

References

Aug 15, 1994·Annals of Internal Medicine·A G JohnsonR O Day
Oct 9, 1999·The American Journal of Pathology·U SchönbeckP Libby
May 29, 2000·Archives of Internal Medicine·A WheltonG S Geis
Nov 23, 2000·The New England Journal of Medicine·C BombardierUNKNOWN VIGOR Study Group
Aug 11, 2001·The New England Journal of Medicine·G A FitzGerald, C Patrono
Jan 17, 2002·The New England Journal of Medicine·R S VasanD Levy
Mar 23, 2002·The American Journal of Cardiology·Raymond C Harris
Mar 23, 2002·The American Journal of Cardiology·William H Frishman
Apr 20, 2002·Science·Yan ChengGarret A FitzGerald
Jan 29, 2003·Circulation·Rémy ChenevardFrank Ruschitzka
Aug 14, 2003·The American Journal of Cardiology·William B WhiteRobert W Makuch
Jan 21, 2004·Hypertension·Hui-Fang Cheng, Raymond C Harris

❮ Previous
Next ❯

Citations

Sep 27, 2005·Digestive Diseases and Sciences·Katya Gudis, Choitsu Sakamoto
Jun 14, 2005·Trends in Endocrinology and Metabolism : TEM·Bukhtiar H Shah
Aug 26, 2009·Respirology : Official Journal of the Asian Pacific Society of Respirology·Yongseon ChoSeung-Ho Han
Aug 2, 2006·Journal of Thrombosis and Haemostasis : JTH·M Van de WouwerE M Conway
Feb 25, 2006·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Zhimin TongJames P Kehrer
Mar 23, 2013·Expert Opinion on Pharmacotherapy·Inoshi Atukorala, David J Hunter
Oct 7, 2011·The Cochrane Database of Systematic Reviews·Jonathan L MarksChristopher J Edwards
Feb 25, 2006·Digestion·Angel Lanas, Carmelo Scarpignato
Jan 4, 2008·The Journal of Behavioral Health Services & Research·Kathryn E McCollisterColleen A Halliday-Boykins
Apr 12, 2019·The Journal of Pharmacology and Experimental Therapeutics·Hirotomo ShimizuHiroshi Kuriyama
Sep 5, 2019·International Journal of Molecular Sciences·Shanzana KhanJaye P F Chin-Dusting
Aug 25, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·A David Rodrigues
Mar 18, 2021·Translational Research : the Journal of Laboratory and Clinical Medicine·Joseph B O'Brien, David L Roman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Related Papers

JAMA : the Journal of the American Medical Association
D MukherjeeE J Topol
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
José A Sánchez-AlcázarAlan J Knox
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
Timothy D Warner, Jane A Mitchell
© 2021 Meta ULC. All rights reserved